Image Ben Hargreaves R&D Mpox is on the rise again as outbreak gathers pace The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures. Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite. R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further. Patients Power to the patients: Patient organisations enabling drug d... Drug development is a complex process and there are many stakeholders involved in bringing treatments to patients. Load more results
R&D Mpox is on the rise again as outbreak gathers pace The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures.
Market Access Drug pricing overhaul sparks tension with industry Up until recently, political rhetoric targeting the pharma industry had been largely all bark and no bite.
R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further.
Patients Power to the patients: Patient organisations enabling drug d... Drug development is a complex process and there are many stakeholders involved in bringing treatments to patients.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
